secwatch.observer — SEC 8-K summary
======================================

Issuer:     Celularity Inc (CELU)
CIK:        0001752828
Form:       8-K
Filed at:   2026-09-29T21:25:51+00:00
Accession:  0001493152-26-044917
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Celularity adds Viome CEO Naveen Jain to board; Diane Parks resigns; fifth director expected
--------------------------------------------------------------------------------

- Naveen Jain, founder and CEO of Viome Life Sciences, appointed to Celularity's board, effective once the Rule 14f-1 information statement process completes.
- Director Diane Parks resigned effective at that same time; Celularity said her decision was not the result of any disagreement over operations, policies or practices.
- Jain's seat comes from board designation rights granted to investors in the September 2026 financing, previously disclosed in the Form 8-K filed September 28, 2026.
- Board now consists of CEO Robert J. Hariri, Peter H. Diamandis, Philip A. Barach and Jain; Celularity said it expects to announce a fifth director shortly.
- Jain receives standard non-employee director compensation, is expected to sign the company's standard indemnification agreement, and has no initial committee assignments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1752828/000149315226044917/0001493152-26-044917-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1752828/000149315226044917/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-044917

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer